The 1AD.AX stock price plunged 20.00% to A$0.004 at market close on 06 Mar 2026, driven by thin volume of 112,972 shares and low market capitalisation of A$587,517.00. This move positions AdAlta Limited (1AD.AX) among today’s top losers on the ASX. We review trading drivers, cash metrics, technical signals and how this affects short-term 1AD.AX stock outlook with data from company filings and market activity.

Price action and trading drivers for 1AD.AX stock

1AD.AX stock fell from an open of A$0.005 to a low of A$0.004 on low liquidity and a volume spike relative to recent intraday flows. This single-day -20.00% decline followed a week where the 50-day average was A$0.00468, suggesting sellers dominated today. The stock’s year high is A$0.01008 and year low is A$0.002, underlining high historical volatility in this biotechnology small cap.

Financial health and key metrics affecting 1AD.AX stock valuation

AdAlta reports an EPS of -0.01 and a negative PE of -0.45, reflecting continued R&D spending. The company shows cash per share of 0.00101 and a current ratio near 0.89, indicating tighter short-term liquidity. Market cap stands at A$587,517.00 with 130,559,400 shares outstanding. These metrics feed into 1AD.AX stock valuation and underline funding risk for a clinical-stage biotech.

Technical outlook and trading indicators for 1AD.AX stock

Technical indicators show mixed short-term momentum for 1AD.AX stock. The RSI at 47.30 is neutral. The 50-day average of A$0.00468 sits above the current price, while the 200-day average of A$0.00338 is below, indicating longer-term support. Volume at 112,972 today is far below average daily volume of 8,333,963, signalling weak liquidity and potential for wider spreads on trades.

Meyka AI rating and analyst context for 1AD.AX stock

Meyka AI rates 1AD.AX with a score of 72.06 out of 100 — Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating from market data shows a separate consensus of C+ dated 05 Mar 2026, reflecting contrasting signals between fundamental scoring and market sentiment.

Risks, catalysts and sector context for 1AD.AX stock

Key risks for 1AD.AX stock include funding needs, clinical trial outcomes for lead drug AD-214, and low liquidity that amplifies price moves. Catalysts include Phase I data readouts, new partnerships or licensing deals. The healthcare sector on ASX shows mixed performance; biotech names often trade on binary clinical milestones, increasing event-driven volatility for 1AD.AX stock.

Forecasts and price targets for 1AD.AX stock

Meyka AI’s forecast model projects a 12-month price target of A$0.008, implying an upside of 100.00% from the current A$0.004. A conservative downside scenario target is A$0.002, implying a -50.00% move. Forecasts are model-based projections and not guarantees. These price targets reflect clinical binary risk, cash runway assumptions and comparable small-cap biotech multiples.

Final Thoughts

AdAlta (1AD.AX) closed as one of the ASX’s top losers on 06 Mar 2026 after a 20.00% drop to A$0.004 on low volume and a market cap of A$587,517.00. The immediate picture is dominated by tight liquidity, negative EPS (-0.01) and a current ratio below 1.00, which together raise near-term funding risk. Meyka AI’s forecast model projects a 12-month target of A$0.008, an implied 100.00% upside from today’s price, balanced by a downside stress target of A$0.002. Our Meyka AI grade (72.06, B+, Suggest BUY) weighs clinical opportunity and sector comparisons against financial strain. Investors focused on 1AD.AX stock should prioritise upcoming clinical updates and cash position disclosures. Use small position sizing, expect high volatility, and treat forecasts as model-based projections, not guarantees. For company announcements, see the AdAlta site and ASX company page for filings and market notices.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.